Xbrane Biopharma AB advances the release of the Year-end report for 2018

Press release
2019-02-20

Xbrane Biopharma AB hereby announce that it has been decided to advance the publication of the Year-end report for the financial year of 2018. The Year-end report will be released on Friday 22 February, 2019 instead of Thursday 28 February, 2019 as previously stated.

For further information, please contact:
Martin Åmark, CEO/IR
M: +46(0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser(corp@avanza.se, +46 (0)8 409 421 20). For more information seewww.xbrane.com.

Xbrane Biopharma advances the release of the year-end report for 2018

—
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xbrane Biopharma AB via Globenewswire